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A B S T R A C T
Recent NIH policy stipulates that multi-site studies must use a single or IRB (Institutional Review Board) in order
to streamline the review process while maintaining standards for human subjects protection. The Western States
Node of the Clinical Trials Network (CTN) used a single IRB for protocol CTN-0067, a clinical trial testing the use
of an opioid antagonist (extended-release naltrexone) versus opioid agonists (buprenorphine or methadone) for
opioid use disorders among individuals living with HIV. This case study discusses the processes and challenges
associated with use of a single IRB. These lessons are also informed by other single IRB experiences within the
CTN. The intention of the NIH single IRB policy is to facilitate efficient IRB processes. Advanced planning and
transparent communication, however, are critical to avoid stalling IRB approval and protocol implementation.
Research teams need to account for local IRB willingness to cede to a single IRB and understand the variations in
interpretations of abbreviated reviews. In order to facilitate the effective use of single IRBs, recommendations
include assigning staff at each study site for IRB submission coordination and interaction with the lead site IRB
staff, training investigators and key regulatory staff on expectations for working with single IRBs, dedicating a
regulatory specialist at the lead site to manage the process, developing a communication plan, and supporting
the development of strong working relationships with local regulatory staff and the single IRB. The CTN ex-
periences with single IRBs may provide insights for other investigators.
1. Introduction
Institutional Review Boards (IRB) ensure that studies with human
subjects are conducted ethically and meet federal standards for con-
ducting research. When trials include multiple study sites and IRBs,
variation in IRB processes and regulatory interpretation may delay
protocol implementation [6,9,15,16]. A study of IRB processes at 16
sites, for example, observed variation in the type of IRB review required
and the number of days from submission to approval (range of 5–172
days) [4]. Expanding numbers of multi-site clinical trials [10] and ob-
servational studies [7], makes the task of managing multiple local IRB
approvals a critical function of health research management and has
implications for the protection of study participants.
Current National Institutes of Health (NIH) policy requires that
domestic centers of multi-site studies funded by NIH use a “single” IRB
to reduce variation and delays [12]. Exceptions are allowed if federal,
tribal, or state laws, regulations and policies prohibit the use of a single
IRB. The NIH can also approve exceptions with compelling justification.
The single IRB requirement does not apply to foreign sites and some
types of NIH awards are exempt (i.e. career development, institutional
training, and fellowship awards) [13]. Though this policy is now active,
little has been documented about the actual use of single IRBs in multi-
site trials. This paper details lessons learned during use of a single IRB
for a National Drug Abuse Treatment Clinical Trials Network (CTN)
protocol, which can provide insight and guidance for other in-
vestigators.
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2. Material and methods
The CTN-0067 “Comparing Treatments for HIV-Infected Opioid
Users in an Integrated Care Effectiveness Study” (CHOICES 2) protocol
was designed to test the use of an opioid antagonist (extended-release
naltrexone) versus treatment as usual with opioid agonists (buprenor-
phine or methadone) for opioid use disorders among individuals living
with HIV. CTN-0067 was based on a two-site pilot study (CTN-0055)
with a small sample (n=51) that demonstrated acceptability and
feasibility of extended-release naltrexone treatment of opioid and/or
alcohol use disorder in HIV clinics [1,8].
The National Institute on Drug Abuse (NIDA) approved the initial
CTN-0067 protocol for site selection and implementation in May 2017.
NIH's policy on the use of single IRB was not effective until January 25,
2018. However, the lead team opted to use a single IRB despite the fact
that the policy was not yet in effect because they hoped to benefit from
the potential for a streamlined process and they hoped to gain experi-
ence, as they knew it would be a requirement in the near future.
Following site selection, development of case report forms, protocol
training, and IRB approvals, seven HIV primary care sites began re-
cruiting study participants in February 2018. Study sites are HIV clinics
with sufficient capacity for new patients to support study enrollment
targets. Teams at each of the seven sites included a medical director and
support staff. Three sites have significant numbers of patients likely to
meet eligibility criteria who speak only Spanish. All sites serve in-
dividuals with a high risk of incarceration, and one site serves geo-
graphically rural communities.
The lead team included the principal investigator, co-investigators,
regulatory specialist, and other research staff, leadership from the CTN
and the Clinical Coordinating Center (CCC), and the Data and Statistics
Center at Emmes, which provides protocol development and on-going
regulatory support, quality assurance monitoring visits, implementa-
tion support and centralized data collection. The lead team's dedicated
regulatory specialist worked with sites and local IRBs to explain the
rationale for a single IRB and encourage them to cede review. She also
served as a liaison between the single IRB, the CCC and regulatory staff
at participating sites to streamline the process. The regulatory specialist
received and sent information from and to the single IRB and local sites;
sites did not typically communicate directly with the single IRB. During
the weekly lead team and all-sites meetings, the regulatory specialist
summarized IRB-related activities. She had strong, positive working
relationships with contacts at the single IRB and regulatory staff at all
participating research sites. Iterative conversations with the single IRB
and the CCC articulated a plan for IRB submission (e.g., number of sites
ceding, documents to be submitted for review, and proposed study
timeline) and ensured that site regulatory staff understood the process
for document submission (e.g., required documents, who is responsible,
and the location of documents). The regulatory specialist and CCC
developed and provided document templates for local adaptation, when
appropriate.
The CTN's clinical coordinating center contracted with a commer-
cial IRB to serve as the single IRB. One IRB declined to cede review and
required a traditional full review. This site was a county health de-
partment and unfamiliar with ceding and they did not have policies in
place to authorize it. Three sites technically ceded but required an
abbreviated review of all study documents and amendments to ensure
that the protocol met university standards. One of those sites required
an abbreviated review from two IRBs because an affiliated investigator
had appointments at two different universities, each of which needed to
cede review to the single IRB. Finally, local IRBs for three sites fully
ceded review.
All sites that ceded review were required to submit an investigator's
application to the single IRB. These applications provided brief details
regarding, roles, credentials, and potential financial interests of the
investigators and research staff, and site contact information as well as
study population, expected enrollment, recruitment methods, consent
process, privacy and confidentiality measures, and local regulations.
The regulatory specialist worked with sites to prepare the institutional
authorization/reliance agreements between the single IRB and local
IRBs, which stipulated that local IRBs would rely on the single IRB for
oversight of the study.
According to these reliance agreements, the single IRB served as the
privacy office for the sites that ceded review. Per the single IRB's re-
quirements, the lead investigator was responsible for ensuring that
study personnel had were appropriately trained for conducting the
study (based on their roles). Site investigators were responsible for
ensuring conflict of interest disclosures were completed for their sites.
In addition, the reliance agreements for the sites included submission of
all consent documents and the protocol. However, one local IRB also
required review of the qualitative interview information sheets. See
Fig. 1 for more information about site ceding.
3. Results
The process from protocol development to IRB approval of all seven
sites was iterative and complex. NIDA approved the protocol in May
2017. Initially, the lead team submitted the protocol to the lead team's
university IRB in June 2017 but the IRB reported that it would not be
able to serve as the single IRB. After approximately a month's delib-
eration, the lead team selected a commercial IRB to serve as the single
IRB and in August 2017, submitted the protocol. Results focus on the
following: ceding review, fees associated with a commercial IRB, and
IRB concerns related to recruiting from jails.
Ceding review. The single IRB required a few amendments, but
these were relatively minor consent form revisions and were addressed
by the regulatory specialist in consultation with the sponsor and
Fig. 1. Diagram of IRB ceding.
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principal investigator. Even with the revisions required by the single
IRB, study documents were approved quickly, approximately two weeks
after the initial submission. For the three sites that ceded review en-
tirely, IRB review was also quick. Sites submitted their investigator
applications and were added to the protocol in September 2017. The
single IRB approved all three of the sites by the end of October 2017.
For the three sites that required abbreviated reviews, local IRBs
conducted these reviews independent from the single IRB. Abbreviated
reviews took anywhere from about 2 weeks to as many as 4 months to
complete. For the site with a 2-week abbreviated review, the local IRB
conducted its review before ceding review to the single IRB. Two weeks
later, the site submitted the investigator application and received ap-
proval from the single IRB in one week.
The site that required two local IRB abbreviated reviews had
varying experiences with each. The first local IRB conducted its ab-
breviated review in a little over 2 weeks by mid-October and ceded
review at that point. The second local IRB did not come to a decision
about ceding review until a month after the first local IRB had already
ceded review. After completing an abbreviated review, the second local
IRB indicated it would cede review, but not until after the site had
received approval by the single IRB. The regulatory specialist submitted
the site's application to the single IRB near the end of November 2017
and the single IRB approved it by the end of December 2017. The site
then resubmitted the protocol and consent forms along with doc-
umentation of the single IRB approval. Near the end of January 2018,
the second local IRB requested additional clarification. After the site
responded to this request, the second local IRB officially ceded review
the second week of February 2018.
Finally, the site with the longest abbreviated review was also the
site whose local IRB requested changes to the qualitative interview
information sheet. The local IRB officially ceded review mid-November
2017 at which point, the site submitted their investigator application.
Once the site received approval from the single IRB near the end of
November 2017, they submitted the protocol, consent forms, and other
study documents requested. Despite ceding review, the local IRB re-
quested changes that were outside the scope of local context informa-
tion. The single IRB worked with the local IRB on these revisions but the
site did not receive approval from the local IRB until the second week of
February 2018, four months after initial submission of the application
to the local IRB. In addition, this same site was also required to submit
the protocol to their institution's Clinical Research Unit after receiving
local IRB approval, further delaying study recruitment.
For the one site that refused to cede, there was uncertainty about
whether the local IRB would agree to cede and it took about two
months for the local IRB to make a decision. Once the local IRB decided
that it would not cede review, the application was submitted near the
end of September 2017. Final approval of the application was received
the first week of December 2017. IRB approval for this site took about
two months longer than for the sites that ceded review entirely.
However, despite concerns that a full review would significantly delay
the process, the site actually received IRB approval two months sooner
than two sites that ceded but required abbreviated reviews. In all, five
IRBs required some level of protocol review. Two of the sites that re-
quired abbreviated reviews had significant delays and during this time,
recruitment was on hold for those sites. This had implications for the
entire study and all sites. Sites that had already received IRB approval
had hired their staff and were ready to begin recruitment. However, as
soon as those sites started recruitment, it “started the clock” with the
sponsor in terms of the recruitment window and budgets allocated for
the duration of the study for all sites. See Fig. 2 for summary of the
timeline of IRB approval.
Fees. Commercial IRBs fee structures can be complicated and re-
quire charges for the initial submission, modifications to submissions
and annual continuing reviews. There were also fees for the review of
every document specific to each study site (local recruitment flyers,
reminder cards, holiday cards, appointment cards, etc.). Participating
sites required consent forms specific to their location (local contact
information, local lead investigator's information) with additional fees
if there was a change of site investigator or site addresses after the
initial review. In addition, there were fees for reviewing/acknowl-
edgment of all certified translated documents (informed consent forms,
recruitment materials, and assessments) to be used in the conduct of the
study at sites with the Spanish speaking populations.
Prisoners. The CTN-0067 study does not directly enroll participants
from correctional facilities. However, sites were encouraged to conduct
outreach to jails to encourage prospective participants to enroll upon
their release. These individuals are at a high risk of re-incarceration and
the study anticipated the need to conduct follow-up interviews with
study participants should they be incarcerated after recruitment. The
single IRB had a process for identifying the need and connecting the
regulatory specialist with a representative from Office of Human
Research Protection. The regulatory specialist worked directly the re-
presentative to obtain certification to conduct follow up interviews with
study participants while incarcerated or in court mandated facilities/
programs.
4. Discussion
The CTN-0067 lead team found that using a single IRB offered both
opportunities as well as challenges. The experiences of the CTN-0067
lead team with a single IRB may be helpful to other investigators and
research teams as they implement a single IRB approach for multisite
studies.
Single IRB selection. The lead team anticipated that their uni-
versity would function as the single IRB based on early communications
with their designated university IRB analyst. After NIDA authorized
study implementation, the lead team met with the university IRB chair
to discuss implementation and learned that the university IRB had
limited experience serving as a single IRB for multi-site trials. The IRB
chair believed the additional workload was beyond the IRB's current
staffing capacity for timely review. With the chair's support, the lead
team decided that a commercial IRB would be more efficient and
timelier. The lead team felt it was important to maintain their role of
working with an IRB; thus, in consultation with NIDA, the lead team
opted for a commercial IRB rather than tasking one of the study sites
with that responsibility.
Direct discussions with lead site IRB chairs about capacity and
willingness to serve as the single IRB should be held prior to finalizing
the protocol timeline. A commercial IRB is a solution if the lead site IRB
has limited capacity and experience in the role as a single IRB, but this
adds additional expense.
Ceding Review. Since the NIH policy is now in effect, all local IRBs
(with some exceptions) are required to cede to a single IRB as a con-
dition of site selection and funding. However, the CTN-0067 lead team
found that even when a local IRB agrees to cede review, it is necessary
to clarify if the local IRB requires any additional review or oversight at
the start or throughout the course of the study beyond a submission of
IRB approved documents from the single IRB. Abbreviated reviews have
the potential to delay the process substantially when these reviews are
not limited to ensuring that local language is included in site-specific
consent forms.
Variation in ceding among the IRBs of the research sites requires the
study team to assess local IRBs' willingness to rely on the proposed
single IRB. If the site requires a local IRB review in addition to the
single IRB review, the research team may need to consider other sites
more comfortable with ceding their research oversight. However, some
scholars have expressed concern about the ethical aspects of single
IRBs. Moon [11] argues that as local IRBs are still liable should human
subjects harms occur during a trial, they are more adept at interpreting
local research participation and consent requirements which may differ
between sites.
While local IRBs and regulatory staff should play a role in providing
C. Nichols et al. Contemporary Clinical Trials Communications 14 (2019) 100319
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local context and ensuring compliance with local, state and institutional
policies, clarity about the purpose as well as the scope of abbreviated
local IRB reviews is critical to avoid delaying recruitment. In order to
avoid unexpected delays, investigators should ensure that authorization
agreements stipulate what is allowable in terms of local reviews. Some
reliance agreements, such as the SMART IRB Reliance Agreement [14],
outline the roles and responsibilities of each IRB as well as stipulate
which types of revisions the ceding IRB may request. In the CTN-0067
lead team's experience, however, other reliance agreements, such as an
Institutional Authorization Agreement, leave the guidelines for revision
requests open-ended and allow ceding IRBs to make requests that could
potentially delay study implementation. In situations where the single
Fig. 2. Timeline of IRB approval.
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IRB and the local IRB come to different decisions, the single IRB should
have the final authority, except in situations involving local context,
regulations, and information. However, these potential disagreements
between the single IRB and local IRB can still delay study im-
plementation as it takes time to manage. Funding institutions should
consider the real-world implications for budgets and timelines when
multi-site studies do not cede review in entirety or in part.
Fees. Because CTN-0067 turned to a commercial IRB late in pro-
tocol development, costs associated with use of a commercial IRB were
not included in the approved study budget. Budgets for IRB oversight
may need to account for all the costs associated with the use of com-
mercial or academic institutional IRBs, and timelines may need to be
adjusted as institutions and local sites become familiar with working
with single IRBs.
The following recommendations may help reduce the costs of
working with a commercial IRB. When budgeting for a single IRB,
discuss the need for site-specific materials versus the use of templates.
Once approved, some IRBs allow sites to insert their own contact in-
formation without further approvals. Plan for sites to submit their in-
itial site submission. Commercial IRBs may not allow the modification
of multiple types of documents in one submission (e.g., recruitment
materials should be submitted separately from consent form modifica-
tions). In order to reduce the costs associated with commercial IRBs,
documents should be batched appropriately and submitted together as
one modification to the extent possible to limit fees associated with
each modification submission. The lead team found that having a
process that allows for a designated regulatory specialist to be re-
sponsible for modification submissions for all sites helped streamline
the modification submissions.
If the trial involves documents in languages other than English, the
lead research team or sponsor should identify a translation company
before submission to the IRB. Commercial IRBs sometimes have existing
relationships with translation companies, so it is helpful to indicate the
intention to use translated documents during early negotiations with
the single IRB representatives and understand the cost structure and
submission requirements and possible short cuts with multi-lingual
documents on record with the IRB.
Prisoners. When selecting a single IRB, investigators should ensure
that the IRB can review the study in accordance with the Department of
Health and Human Services' regulations (45 CFR part 46, subpart C)
and provide a prisoner representative to serve on the board reviewing
this protocol. Early in the submission process, the research team should
alert the single IRB that a prisoner representative is required for review
of the study. This is a critical consideration in the IRB selection criteria
and capabilities discussion. Research teams should learn whether the
prisoner representative is an active member of the Board or whether a
special meeting will be required that might delay IRB review.
This paper has described a wide range of learning experiences with
a single IRB from the CTN-0067 study. See Table 1 for a summary of key
lessons learned during the implementation of the CTN-0067 trial. While
there have been limited studies focused on the use of single IRBs, there
are a few experiences with the Single IRB that are similar to CTN-0067
team's experience. For instance, the Tuberculosis Trials Consortium
found that local review was time consuming and also resulted in
changes that decreased the readability of the consent forms [2]. The
Clinical Trials Transformative Initiative found that IRBs conflate in-
stitutional responsibilities with ethical review responsibilities and re-
commended the use of a written document that clearly outlines those
responsibilities for both the Single IRB as well as the local IRBs [5].
Finally, Check et al. completed a literature review of articles on the use
of single IRBs and found that several reported local reviews that were
redundant as well as inefficient and had implications on study re-
cruitment [3].
In order to realize the full benefits of single IRBs, some system-level
changes are necessary. Three actions can help facilitate the effective use
of single IRBs: 1) have dedicated staff at each study site for IRB sub-
mission coordination and interaction with the local IRB staff, 2) train
investigators and key regulatory staff on expectations of working with
single IRBs, and 3) use a regulatory specialist at the lead site who can
manage the entire process, develop a communication plan, and support
the development of strong working relationships with local regulatory
staff and the single IRB.
5. Conclusions
The National Drug Abuse Treatment Clinical Trials Network now
has experience with seven protocols that involved a single IRB using
both commercial IRBs and university IRBs. With experience, logistics
have gone more smoothly. We found that the research sites associated
with a university have had more difficulty ceding to a single IRB,
especially if it is a commercial IRB, than a site not associated with a
university.
The CTN has also learned that IRBs may be inexperienced with
various protocol designs implemented within the CTN and may require
discussion, explanation and modification of IRB processes designed for
typical randomized clinical trials. It is also necessary to educate study
sites to work efficiently with the single IRB. Knowing which sites will
cede, and to what degree, prior to submitting a proposal budget to the
sponsor, enables the projection of more accurate project start dates and
sufficient funding to meet all needs of the research project. An aware-
ness of how different IRB choices may have implications for the pro-
tocol, budget, or implementation process is critical to the project's
success. CTN-0067 was among the first CTN protocols to work with a
commercial IRB and learned through trial and error to become more
efficient and to take full advantage of the single IRB.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.conctc.2019.100319.
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